Likely due to the public outcry from parents of kids with severe allergies about the insane hike in the cost to buy EpiPens, drug maker Mylan has responded with a pledge to immediately increase access to the life-saving medication.
On the company's website, it vows to double "the eligibility for patient assistance," to eliminate the "out-of-pocket expense for uninsured, and under-insured patients." Mylan says it will also "cover up to $300," or about 50 percent, of a patients' expense via a savings card to help with the "out-of-pocket cost."
In the press release, Mylan CEO Heather Bresch, who has come under fire for the fact that her salary skyrocketed at the same time the cost of EpiPens did, said, "We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen Auto-Injector gets one."
Bresch continued, "We recognize the significant burden on patients from continued, rising insurance premiums and being forced increasingly to pay the full list price for medicines at the pharmacy counter. Patients deserve increased price transparency and affordable care, particularly as the system shifts significant costs to them."
She also points to a growing U.S. healthcare crisis, and pledges that Mylan will do its part, but calls on policymakers, payors, patients, and healthcare professionals to also force change.
You can read more about how exactly Mylan plans to help allergy sufferers afford the EpiPen 2-pack, which currently can cost upward of $600, on its website.
What's your take on Mylan's reaction to patients' dissatisfaction?
Melissa Willets is a writer/blogger and a mom. Follow her on Twitter (@Spitupnsuburbs), where she chronicles her love of exercising and drinking coffee, but never simultaneously.